Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Int J Urol
    October 2025
  1. SUZUKI K, Khan N, Taguchi T, Hattori K, et al
    Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
    Int J Urol. 2025 Oct 3. doi: 10.1111/iju.70235.
    >> Share

  2. SASAKI T, Higashi S, Nishikawa T, Sugino Y, et al
    Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A Preliminary Prospective Study.
    Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70251.
    >> Share

  3. YASUDA Y, Yoshida S, Matsubara D, Takahara T, et al
    Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70253.
    >> Share

    September 2025
  4. DENIZ ME, Gur G, Kayra MV, Hasbay B, et al
    PSMA PET/CT and Multiparametric MRI in Assessing Local Extension and Lymph Node Metastasis in Prostate Cancer.
    Int J Urol. 2025 Sep 24. doi: 10.1111/iju.70239.
    >> Share

  5. MIYOSHI Y, Uemura H, Ohta J, Kobayashi K, et al
    Prognostic Value of BONENAVI Computer-Aided Diagnosis System Bone Scans as an Imaging Biomarker for Bone-Metastatic Castration-Sensitive Prostate Cancer: An Investigator-Initiated, Multicenter, Prospective Observational Study.
    Int J Urol. 2025 Sep 23. doi: 10.1111/iju.70214.
    >> Share

  6. HATANO K
    Editorial Comment on "Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis".
    Int J Urol. 2025 Sep 17. doi: 10.1111/iju.70236.
    >> Share

  7. NAKAJIMA Y, Hashimoto K, Shindo T, Kobayashi K, et al
    Prostate-Specific Antigen Dynamics and Bone Predominance as Predictors of Efficacy in Radium-223 Treatment for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Sep 16. doi: 10.1111/iju.70229.
    >> Share

  8. SUZUKI K, Hirata J, Ueki H, Wakita N, et al
    Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis.
    Int J Urol. 2025 Sep 3. doi: 10.1111/iju.70219.
    >> Share

  9. MATSUYAMA N, Suzuki K, Tobe T, Ueki H, et al
    Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Sep 2. doi: 10.1111/iju.70217.
    >> Share

  10. KAWASE M
    Editorial Comment Regarding "Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection".
    Int J Urol. 2025 Sep 1. doi: 10.1111/iju.70218.
    >> Share

    August 2025
  11. ARAI S
    Editorial Comment on Efficacy of Docetaxel Addition to Next-Generation Androgen Receptor-Axis-Targeted Therapies and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Tumor Volume-Specific Analysis.
    Int J Urol. 2025 Aug 21. doi: 10.1111/iju.70208.
    >> Share

  12. IWAMOTO H, Hori T, Inaba T, Nakagawa R, et al
    Prognostic Impact of Time to Castration Resistance on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70197.
    >> Share

  13. SHIMOMURA T
    Editorial Comment to "Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study".
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70185.
    >> Share

  14. YAMAMOTO Y, Fujimoto S, Hashimoto M, Minami T, et al
    Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70202.
    >> Share

  15. ARAI S
    Editorial Comment on Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
    Int J Urol. 2025 Aug 10. doi: 10.1111/iju.70201.
    >> Share

  16. TOHI Y, Kato T, Fujiwara K, Harada S, et al
    Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection.
    Int J Urol. 2025 Aug 3. doi: 10.1111/iju.70193.
    >> Share

  17. SOMOTO T, Utsumi T, Ishitsuka N, Noro T, et al
    Clinical Predictors of Fluoroquinolone-Resistant Escherichia coli in Transrectal Ultrasound-Guided Prostate Biopsy: Insights for Tailored Prophylaxis.
    Int J Urol. 2025;32:982-989.
    >> Share

    July 2025
  18. HIRATA H
    Editorial Comment on "Frontiers of Ultrasound Technology in Prostate Cancer Treatment".
    Int J Urol. 2025 Jul 19. doi: 10.1111/iju.70183.
    >> Share

  19. MITSUI Y, Nakajima K
    Editorial Comment on "Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy".
    Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70166.
    >> Share

    June 2025
  20. SHOJI S, Takahashi K, Naruse J, Kawamura Y, et al
    Frontiers of Ultrasound Technology in Prostate Cancer Treatment.
    Int J Urol. 2025 Jun 22. doi: 10.1111/iju.70160.
    >> Share

  21. TASHIRO K, Mori K, Shiota M, Fukuokaya W, et al
    Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70149.
    >> Share

  22. YASUDA Y, Numao N, Matsumoto S, Tamiya T, et al
    Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70154.
    >> Share

  23. WATANABE R
    Editorial Comment to "VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m6A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species".
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70150.
    >> Share

  24. OKUDA Y, Kato T, Ishizuya Y, Hayashi T, et al
    PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer.
    Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70100.
    >> Share

  25. PATTOU M, Neuzillet Y, Ghoneim T, Bosset PO, et al
    Evaluating the Safety of Delaying Surgery Beyond 9 Months in Localized Prostate Cancer Patients: Results From a Prospective Study With Propensity Score Matching.
    Int J Urol. 2025 Jun 4. doi: 10.1111/iju.70142.
    >> Share

  26. MA J, Qu X
    VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m(6)A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species.
    Int J Urol. 2025 Jun 3. doi: 10.1111/iju.70140.
    >> Share

  27. FALKENBACH F, Penaranda NR, Longoni M, Marmiroli A, et al
    The Effect of Chronic Kidney Disease on Adverse In-Hospital Outcomes at Radical Prostatectomy.
    Int J Urol. 2025;32:710-717.
    >> Share

  28. KIMURA Y, Honda M, Yamane H, Shimizu R, et al
    Outcomes in Health-Related Quality of Life and Impact of Urinary Incontinence on Health-Related Quality of Life 7 Years After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:664-671.
    >> Share

    May 2025
  29. ZHAO X, Sakamoto S, Yamada Y, Sato K, et al
    The Role of Serum Testosterone in the Pathogenesis and Treatment of Prostate Cancer: A Review Based on the Clinical Evidence.
    Int J Urol. 2025 May 23. doi: 10.1111/iju.70125.
    >> Share

  30. REIKE MJ, Tully KH, Schulmeier M, Reicherz A, et al
    Functional Outcomes in Patients With Prostate Cancer Undergoing Frozen Section Guided Radical Prostatectomy.
    Int J Urol. 2025 May 20. doi: 10.1111/iju.70115.
    >> Share

  31. HATANO K
    Editorial Comment on "Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?".
    Int J Urol. 2025 May 7. doi: 10.1111/iju.70093.
    >> Share

    April 2025
  32. ROLDAN-TESTILLANO R, Sanchez-Salas R
    Editorial Comment on "Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study".
    Int J Urol. 2025 Apr 25. doi: 10.1111/iju.70083.
    >> Share

  33. NORO T, Utsumi T, Ishitsuka N, Suzuki Y, et al
    Impact of the COVID-19 Pandemic on Prostate Cancer: Perturbations in Screening and Diagnostic Patterns.
    Int J Urol. 2025 Apr 24. doi: 10.1111/iju.70085.
    >> Share

  34. CHEN W, Yoshida S, Fujii Y
    Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?
    Int J Urol. 2025 Apr 17. doi: 10.1111/iju.70072.
    >> Share

  35. BLAS L, Shiota M, Kato T, Matsumoto R, et al
    Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study.
    Int J Urol. 2025 Apr 7. doi: 10.1111/iju.70063.
    >> Share

  36. DLAMINI KCS, Coetzee LJ, Mathabe K
    South African single surgeon experience: Comparison of oncological outcomes, robot-assisted radical prostatectomy versus open perineal radical prostatectomy.
    Int J Urol. 2025;32:423-426.
    >> Share

  37. FUNAJIMA K, Naito S, Fukai A, Narisawa T, et al
    Urinary continence outcomes after robot-assisted laparoscopic radical prostatectomy: Significance of anterior reconstruction.
    Int J Urol. 2025;32:355-360.
    >> Share

  38. KAWAMURA N, Nakayama M, Hayashi T, Nagahara A, et al
    Risk assessment of late biochemical recurrence after radical prostatectomy: Usefulness of ultra-sensitive prostate-specific antigen measurement.
    Int J Urol. 2025;32:380-386.
    >> Share

    March 2025
  39. YAMAMOTO Y
    Editorial Comments to "Overuse of Imaging in Prostate Cancer Staging".
    Int J Urol. 2025 Mar 24. doi: 10.1111/iju.70021.
    >> Share

  40. SEKINE Y, Fujizuka Y, Nakazawa S, Tsuji Y, et al
    Utility of Combining Prostate Health Index and Magnetic Resonance Imaging for the Diagnosis of Prostate Cancer.
    Int J Urol. 2025 Mar 17. doi: 10.1111/iju.70024.
    >> Share

  41. ONISHI K, Nakai Y, Tachibana A, Nishimura N, et al
    Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose-Rate Brachytherapy for Prostate Cancer.
    Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70018.
    >> Share

  42. SEKITO T, Sadahira T
    Editorial Comment on Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose Rate Brachytherapy for Prostate Cancer.
    Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70035.
    >> Share

  43. GUNGE N, Fukuhara Y, Matsuoka W, Fumihiro Y, et al
    Effect of ICG fluorescence-assisted new nerve-sparing of robot-assisted radical prostatectomy on lower urinary tract symptoms.
    Int J Urol. 2025;32:285-292.
    >> Share

  44. MITSUI M, Sadahira T, Nagasaki N, Maruyama Y, et al
    Postoperative infections after robotic-assisted radical prostatectomy in a single large institution: Effect of type and duration of prophylactic antibiotic administration.
    Int J Urol. 2025;32:258-263.
    >> Share

    February 2025
  45. MATSUOKA Y
    Editorial Comment to "Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer".
    Int J Urol. 2025 Feb 27. doi: 10.1111/iju.70031.
    >> Share

  46. SUZUKI K, Matsuyama H, Matsubara N, Kazama H, et al
    Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.
    Int J Urol. 2025 Feb 25. doi: 10.1111/iju.70019.
    >> Share

  47. URABE F, Kimura S
    Considerations on the Optimal Imaging for Prostate Cancer Diagnosis.
    Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70016.
    >> Share

  48. HSIEH PF, Naruse J, Yuzuriha S, Umemoto T, et al
    Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer.
    Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70013.
    >> Share

  49. IWAMOTO H, Izumi K, Mizokami A
    Editorial Comment on the Overuse of Imaging in Prostate Cancer Staging.
    Int J Urol. 2025 Feb 17. doi: 10.1111/iju.70015.
    >> Share

  50. TOHI Y, Kato T, Kohashiguchi K, Kaji A, et al
    Overuse of imaging in prostate cancer staging.
    Int J Urol. 2025 Feb 3. doi: 10.1111/iju.70003.
    >> Share

  51. HIROSE K, Nakanishi Y, Ogasawara RA, Imasato N, et al
    Risk factors for rectal wall infiltration in hydrogel spacer placement: Influence of biopsy approach.
    Int J Urol. 2025;32:183-189.
    >> Share

  52. MINAMI T, Fujimoto S, Fujita K
    Iodine-125 low-dose rate prostate brachytherapy.
    Int J Urol. 2025;32:130-137.
    >> Share

    January 2025
  53. ARAI S
    Editorial Comment on "Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study".
    Int J Urol. 2025 Jan 21. doi: 10.1111/iju.15682.
    >> Share

  54. WASHINO S, Saito K, Yazaki K, Miyagawa T, et al
    A novel anterior approach toward robotic radical prostatectomy is associated with earlier continence recovery than the conventional approach.
    Int J Urol. 2025;32:80-87.
    >> Share

  55. KOBAYASHI K, Nofuji S, Okabe K, Yorozuya W, et al
    How do Japanese patients really feel about losing potency after radical prostatectomy? (MAJI study).
    Int J Urol. 2025;32:69-72.
    >> Share

  56. TEISHIMA J, Wakita N, Bando Y, Okamura Y, et al
    Effects of modifying hinotori surgical robot system on perioperative outcome of robot-assisted radical prostatectomy.
    Int J Urol. 2025;32:45-50.
    >> Share

    December 2024
  57. CHEN W, Yoshida S, Miura N, Fukuda S, et al
    Efficacy of docetaxel addition to next-generation androgen receptor-axis-targeted therapies and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A tumor volume-specific analysis.
    Int J Urol. 2024 Dec 20. doi: 10.1111/iju.15657.
    >> Share

  58. KUMAR V, Jena D, Zahiruddin QS, Roopashree R, et al
    Prostate cancer burden in South Asia: A systematic analysis of global burden of disease data (1990-2021).
    Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15641.
    >> Share

  59. SUZUKI H, Akamatsu S, Shiota M, Kakiuchi H, et al
    Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15647.
    >> Share

  60. YE DW, Uemura H, Chung BH, Suzuki H, et al
    Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15615.
    >> Share

  61. MORIZANE S, Miki J, Shimbo M, Kanno T, et al
    Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
    Int J Urol. 2024;31:1300-1310.
    >> Share

    November 2024
  62. HAKOZAKI Y, Yamada Y, Fujimura T, Kimura N, et al
    Novel clipping procedure for preventing post-operative inguinal hernia in robot-assisted radical prostatectomy.
    Int J Urol. 2024;31:1241-1247.
    >> Share

    October 2024
  63. OBINATA D, Yamada Y, Sumiyoshi T, Tanegashima T, et al
    Recent advances in basic research on prostate cancer: Where we are heading?
    Int J Urol. 2024 Oct 30. doi: 10.1111/iju.15628.
    >> Share

  64. SHIOTA M
    Editorial Comment to Loss of phosphatase and tensin homolog expression in castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
    Int J Urol. 2024 Oct 15. doi: 10.1111/iju.15607.
    >> Share

  65. SATO M, Osawa T, Nishioka K, Miyazaki T, et al
    Decision regret after curative treatment and its association with the decision-making process and quality of life for prostate cancer patients.
    Int J Urol. 2024 Oct 9. doi: 10.1111/iju.15602.
    >> Share

  66. YANAI Y, Mikami S, Yasumizu Y, Takeda T, et al
    Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
    Int J Urol. 2024 Oct 1. doi: 10.1111/iju.15592.
    >> Share

  67. KOHADA Y, Kitano H, Tasaka R, Miyamoto S, et al
    Clinical characteristics and predictors of long-term postoperative urinary incontinence in patients treated with robot-assisted radical prostatectomy: A propensity-matched analysis.
    Int J Urol. 2024;31:1145-1152.
    >> Share

    September 2024
  68. MITSUI Y, Nakajima K
    Editorial Comment to "Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis".
    Int J Urol. 2024 Sep 26. doi: 10.1111/iju.15582.
    >> Share

  69. GUO X, Zhang F, Hao G
    Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis.
    Int J Urol. 2024 Sep 22. doi: 10.1111/iju.15565.
    >> Share

  70. SHIMADA K, Fujiwara M, Hirahara D, Takaya E, et al
    Monitoring prostate cancer after low-dose-rate hemigland brachytherapy with delta-radiomics of diffusion-weighted magnetic resonance imaging.
    Int J Urol. 2024 Sep 11. doi: 10.1111/iju.15581.
    >> Share

  71. KAMBE T, Yamasaki T, Yamamoto A, Nagoshi A, et al
    Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
    Int J Urol. 2024 Sep 10. doi: 10.1111/iju.15579.
    >> Share

  72. KATO T, Tohi Y, Okazoe H, Taoka R, et al
    How widespread is active surveillance of early-stage prostate cancer in Japan? Multicenter questionnaire survey on the status of active surveillance of early-stage prostate cancer in Japan.
    Int J Urol. 2024 Sep 4. doi: 10.1111/iju.15573.
    >> Share

  73. MORITA M, Hiramatsu A, Nishimura K, Yanagida W, et al
    Radiation proctitis after iodine-125 low-dose-rate prostate brachytherapy utilizing SpaceOAR hydrogel.
    Int J Urol. 2024;31:1001-1008.
    >> Share

  74. COLAKOGLU Y, Eksi M, Ozlu DN, Simsek A, et al
    Comparison of oncological and functional results of robotic and open perineal radical prostatectomy.
    Int J Urol. 2024;31:994-1000.
    >> Share

    August 2024
  75. MATSUOKA Y
    Editorial Comment to "Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?".
    Int J Urol. 2024 Aug 24. doi: 10.1111/iju.15566.
    >> Share

  76. MIURA H, Hatakeyama S, Tabata R, Fujimori D, et al
    Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.
    Int J Urol. 2024 Aug 23. doi: 10.1111/iju.15550.
    >> Share

  77. MADENDERE S, Kilic M, Gurses B, Vural M, et al
    Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?
    Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15553.
    >> Share

  78. GOTO Y
    Editorial Comment on Japanese clinical practice guidelines for prostate cancer 2023.
    Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15562.
    >> Share

  79. URABE F, Kimura S, Tashiro K
    Is meta-analysis effective in evaluating local treatment benefits for oligometastatic prostate cancer?
    Int J Urol. 2024 Aug 1. doi: 10.1111/iju.15555.
    >> Share

  80. TOHI Y, Osaki Y, Kato T, Honda T, et al
    Impact of the coronavirus disease pandemic on robot-assisted radical prostatectomy and urologists' treatment behaviors: A single tertiary center retrospective study.
    Int J Urol. 2024;31:899-905.
    >> Share

    July 2024
  81. KOHJIMOTO Y, Uemura H, Yoshida M, Hinotsu S, et al
    Japanese clinical practice guidelines for prostate cancer 2023.
    Int J Urol. 2024 Jul 30. doi: 10.1111/iju.15545.
    >> Share

  82. URABE F, Muramoto K, Yanagisawa T, Fukuokaya W, et al
    Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
    Int J Urol. 2024 Jul 19. doi: 10.1111/iju.15546.
    >> Share

  83. AIZAWA R, Ishikawa H, Kato M, Shimizu S, et al
    Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.
    Int J Urol. 2024 Jul 17. doi: 10.1111/iju.15535.
    >> Share

  84. SUN Q, Du K, Sun S, Liu Y, et al
    Local treatment benefits patients with oligometastatic prostate cancer: A systematic review and meta-analysis.
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15540.
    >> Share

  85. DELLA CORTE M, Checcucci E
    Editorial Comment on "The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery".
    Int J Urol. 2024 Jul 9. doi: 10.1111/iju.15543.
    >> Share

  86. DI BELLO F, Fraia A, Pezone G, Colla Ruvolo C, et al
    The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery.
    Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15516.
    >> Share

    June 2024
  87. SAITO K, Kohada Y, Hieda K, Shikuma H, et al
    Preoperative high serum total testosterone levels predict preserved postoperative sexual function in patients after nerve-sparing robot-assisted radical prostatectomy.
    Int J Urol. 2024 Jun 7. doi: 10.1111/iju.15511.
    >> Share

  88. TANABE K, Kobayashi S, Tamiya T, Konishi T, et al
    Risk factors for the long-term persistent genitourinary toxicity after stereotactic body radiation therapy for localized prostate cancer: A single-center, retrospective study of 306 patients.
    Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15507.
    >> Share

  89. HASHIMOTO K, Kosaka T, Terada N, Kimura T, et al
    Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023.
    Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15499.
    >> Share

  90. KATO M, Shiota M, Kimura T, Hanazawa R, et al
    Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
    Int J Urol. 2024;31:662-669.
    >> Share

    May 2024
  91. WATANABE H, Nakane K, Takahara K, Naiki T, et al
    Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
    Int J Urol. 2024 May 19. doi: 10.1111/iju.15498.
    >> Share

  92. URABE F
    The relevance of circRNAs in serum of patients undergoing prostate biopsy.
    Int J Urol. 2024;31:581.
    >> Share

  93. SAMIRAE L, Krausewitz P, Alajati A, Kristiansen G, et al
    The relevance of circRNAs in serum of patients undergoing prostate biopsy.
    Int J Urol. 2024;31:578-580.
    >> Share

  94. CHIARELLI G, Davis M, Stephens A, Cirulli GO, et al
    Comparison of patient background between a real-world North American cohort and the Goteborg-2 trial.
    Int J Urol. 2024;31:562-567.
    >> Share

  95. ANDO S, Sugihara T, Hinotsu S, Kishino H, et al
    Early recovery of urinary continence after robot-assisted radical prostatectomy is associated with membranous urethra and neurovascular bundle preservation.
    Int J Urol. 2024;31:492-499.
    >> Share

    April 2024
  96. YAMAMOTO Y, Nonomura N
    Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Int J Urol. 2024 Apr 4. doi: 10.1111/iju.15458.
    >> Share

  97. BLAS L, Shiota M, Tanegashima T, Tsukahara S, et al
    Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
    Int J Urol. 2024;31:404-408.
    >> Share

    March 2024
  98. URABE F, Sumiyoshi T, Tashiro K, Goto T, et al
    Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15441.
    >> Share

  99. GOTO Y
    Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15456.
    >> Share

  100. KOBAYASHI M, Matsuoka Y, Uehara S, Tanaka H, et al
    Utility of positive core number on MRI-ultrasound fusion targeted biopsy in combination with PI-RADS scores for predicting unexpected extracapsular extension of clinically localized prostate cancer.
    Int J Urol. 2024 Mar 12. doi: 10.1111/iju.15451.
    >> Share

  101. GOTO Y
    Editorial Comment on Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
    Int J Urol. 2024 Mar 8. doi: 10.1111/iju.15444.
    >> Share

  102. KAWASE M, Kato D, Tobisawa Y, Iinuma K, et al
    Efficacy and safety of combination neoadjuvant chemo-hormonal therapy and robot-assisted radical prostatectomy for oligometastatic prostate cancer.
    Int J Urol. 2024 Mar 7. doi: 10.1111/iju.15448.
    >> Share

  103. BLAS L, Shiota M, Tanegashima T, Kobayashi S, et al
    Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Int J Urol. 2024 Mar 5. doi: 10.1111/iju.15449.
    >> Share

    February 2024
  104. PARK SJ, Park YJ, Park SM
    Response to comment: Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
    Int J Urol. 2024 Feb 15. doi: 10.1111/iju.15431.
    >> Share

  105. OBINATA D, Takayama K, Inoue S, Takahashi S, et al
    Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
    Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15424.
    >> Share

  106. ASAI S, Kobayashi M, Fukuda S, Kimura K, et al
    Significance of atypical nodules upgraded to category 3 in Prostate Imaging Reporting and Data System version 2.1 for prostate cancer diagnosis.
    Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15421.
    >> Share

  107. HIYAMA Y
    Editorial Comment: Proctoscopy following transrectal prostate biopsy can control rectal bleeding after prostate biopsy.
    Int J Urol. 2024;31:143.
    >> Share

    January 2024
  108. SHOJI S
    Editorial Comment to Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
    Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15406.
    >> Share

  109. LIN YH, Chen YT, Tsai HY
    Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
    Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15401.
    >> Share

  110. MORI K
    Editorial Comment from Dr Mori to Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
    Int J Urol. 2024 Jan 24. doi: 10.1111/iju.15402.
    >> Share

  111. HATANO K
    Editorial Comment on "Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea".
    Int J Urol. 2024 Jan 12. doi: 10.1111/iju.15393.
    >> Share

  112. UKIMURA O
    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
    >> Share

  113. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    >> Share

  114. OKIHARA K, Ueda T, Fujihara A, Shiraishi T, et al
    Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15389.
    >> Share

  115. OKANO K, Miyai K, Mikoshi A, Edo H, et al
    Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15385.
    >> Share

  116. DE VELASCO MA, Kura Y, Fujita K, Uemura H, et al
    Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
    Int J Urol. 2024 Jan 2. doi: 10.1111/iju.15378.
    >> Share

  117. NAITO Y, Kato M, Nagayama J, Sano Y, et al
    Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
    Int J Urol. 2024;31:7-16.
    >> Share

    December 2023
  118. YOKOMIZO A, Shiota M, Morokuma F, Eto M, et al
    GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
    Int J Urol. 2023 Dec 26. doi: 10.1111/iju.15371.
    >> Share

  119. PARK SJ, Hong J, Park YJ, Jeong S, et al
    Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
    Int J Urol. 2023 Dec 21. doi: 10.1111/iju.15364.
    >> Share

  120. NAKAZONO M, Urabe F, Iwatani K, Imai Y, et al
    Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
    Int J Urol. 2023;30:1147-1154.
    >> Share

    November 2023
  121. YUASA T
    Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
    Int J Urol. 2023;30:1034-1035.
    >> Share

  122. SHIRAISHI K
    Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire.
    Int J Urol. 2023;30:959-967.
    >> Share

  123. BLAS L, Shiota M, Matsumoto T, Hori Y, et al
    Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
    Int J Urol. 2023;30:1029-1034.
    >> Share

  124. KOHADA Y, Hieda K, Miyamoto S, Tasaka R, et al
    Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:1020-1027.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016